Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States
Open Access
Abstract
The field of natriuretic peptides (NPs) as an endocrine hormone has been developing since 1979. There are three peptides in humans: atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), which bind to the guanylyl cyclase-A (GC-A) receptor (also called natriuretic peptide receptor-A (NPR-A)), and C-type natriuretic peptide (CNP), which binds to the GC-B receptor (also called the NPR-B) and then synthesizes intracellular cGMP. GC-A receptor stimulation has natriuretic, vasodilatory, cardiorenal protective and anti-renin–angiotensin–aldosterone system actions, and GC-B receptor stimulation can suppress myocardial fibrosis and can activate bone growth before epiphyseal plate closure. These physiological effects are useful as therapeutics for some disease states, such as heart failure, hypertension, and dwarfism. To optimize the therapeutics for each disease state, we must consider drug metabolism, delivery systems, and target receptor(s). We review the cardiac NP system; new designer NPs, such as modified/combined NPs and modified peptides that can bind to not only NP receptors but receptors for other systems; and oral drugs that enhance endogenous NP activity. Finally, we discuss prospective drug discoveries and the development of novel NP therapeutics.Keywords
Funding Information
- JSPS (Japan Society for the Promotion of Science) (#JP22K08675)
This publication has 79 references indexed in Scilit:
- Evaluation of the Therapeutic Potential of a CNP Analog in a Fgfr3 Mouse Model Recapitulating AchondroplasiaThe American Journal of Human Genetics, 2012
- Sustained Blood Pressure–Lowering Actions of Subcutaneous B-Type Natriuretic Peptide (Nesiritide) in a Patient With Uncontrolled HypertensionMayo Clinic Proceedings, 2012
- Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytesJournal of Clinical Investigation, 2012
- Ghrelin and growth hormone: Story in reverseProceedings of the National Academy of Sciences, 2010
- A Human Atrial Natriuretic Peptide Gene Mutation Reveals a Novel Peptide With Enhanced Blood Pressure-Lowering, Renal-Enhancing, and Aldosterone-Suppressing ActionsJACC, 2009
- Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptideProceedings of the National Academy of Sciences, 2009
- A Familial Mutation Renders Atrial Natriuretic Peptide Resistant to Proteolytic DegradationJournal of Biological Chemistry, 2009
- Pharmacodynamics Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD‐NP, in a First‐in‐Human Clinical Trial in Healthy SubjectsThe Journal of Clinical Pharmacology, 2009
- Atrial Natriuretic Peptide Frameshift Mutation in Familial Atrial FibrillationNew England Journal of Medicine, 2008
- Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NPJACC, 2008